Literature DB >> 20305616

Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.

Aldo Scarpa1, William Mantovani, Paola Capelli, Stefania Beghelli, Letizia Boninsegna, Rossella Bettini, Francesco Panzuto, Paolo Pederzoli, Gianfranco delle Fave, Massimo Falconi.   

Abstract

Pancreatic endocrine tumors are rare diseases and devising a clinically effective prognostic stratification of patients is a major clinical challenge. This study aimed at assessing whether the tumor-node-metastasis (TNM)-based staging and proliferative activity-based grading recently proposed by the European NeuroEndocrine Tumors Society (ENETS) have clinical value. TNM was applied to 274 patients with histologically diagnosed pancreatic endocrine tumors operated from 1991 to 2005, with last follow-up at December 2007. According to World Health Organization (WHO) classification, 246 were well-differentiated neoplasms (51 benign, 56 uncertain behavior, 139 carcinomas) and 28 poorly differentiated carcinomas. Grading was based on Ki67 immunohistochemistry. Survival analysis not only ascertained the prognostic value of the TNM system but also highlighted that in the absence of nodal and distant metastasis, infiltration and tumor dimensions over 4 cm had prognostic significance. T parameters were then appropriately modified to reflect this weakness. The 5-year survival for modified TNM stages I, II, III and IV were 100, 93, 65 and 35%, respectively. Multivariate analysis identified TNM stages as independent predictors of death, in which stages II, III and IV showed a risk of death of 7, 29 and 58 times higher than stage I tumors (P<0.0001). Ki67-based grading resulted an independent predictor of survival with cut-offs at 5 and 20%. In conclusion, WHO classification assigns clinically significant diagnostic categories to pancreatic endocrine tumors that need prognostic stratification by applying a staging system. The ENETS-TNM provides the best option, but it requires some modifications to be fully functional. The modified TNM described in this study ameliorates the clinical applicability and prediction of outcome of the ENETS-TNM; it (i) assigns a risk of death proportional to the stage at the time of diagnosis, and (ii) allows a clinically based staging of patients, as the T parameters as modified permit their clinical-radiological recognition. Ki67-based grading discerns prognosis of patients with same stage diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20305616     DOI: 10.1038/modpathol.2010.58

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  125 in total

1.  [The ENETS and UICC TNM classification of neuroendocrine tumors of the gastrointestinal tract and the pancreas: comment].

Authors:  G Klöppel; G Rindi; A Perren; P Komminoth; D S Klimstra
Journal:  Pathologe       Date:  2010-09       Impact factor: 1.011

2.  The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement.

Authors:  Günter Klöppel; Guido Rindi; Aurel Perren; Paul Komminoth; David S Klimstra
Journal:  Virchows Arch       Date:  2010-04-27       Impact factor: 4.064

3.  Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.

Authors:  Lingaku Lee; Hisato Igarashi; Nao Fujimori; Masayuki Hijioka; Ken Kawabe; Yoshinao Oda; Robert T Jensen; Tetsuhide Ito
Journal:  Jpn J Clin Oncol       Date:  2015-09-15       Impact factor: 3.019

4.  Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes.

Authors:  Christina L Roland; Aihua Bian; John C Mansour; Adam C Yopp; Glen C Balch; Rohit Sharma; Xian-Jin Xie; Roderich E Schwarz
Journal:  J Surg Oncol       Date:  2011-10-17       Impact factor: 3.454

5.  CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study.

Authors:  Dongsheng Gu; Yabin Hu; Hui Ding; Jingwei Wei; Ke Chen; Hao Liu; Mengsu Zeng; Jie Tian
Journal:  Eur Radiol       Date:  2019-06-21       Impact factor: 5.315

6.  Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors.

Authors:  Annika Blank; Laura Wehweck; Ilaria Marinoni; Laura Amanda Boos; Frank Bergmann; Anja Maria Schmitt; Aurel Perren
Journal:  Virchows Arch       Date:  2015-09-17       Impact factor: 4.064

7.  Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.

Authors:  Yugang Cheng; Hanxiang Zhan; Lei Wang; Jianwei Xu; Guangyong Zhang; Zongli Zhang; Sanyuan Hu
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

Review 8.  Practical management and treatment of pancreatic neuroendocrine tumors.

Authors:  Naoko Iwahashi Kondo; Yasuharu Ikeda
Journal:  Gland Surg       Date:  2014-11

9.  PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target.

Authors:  Buddha Gurung; Xianxin Hua; Melissa Runske; Bonita Bennett; Virginia LiVolsi; Robert Roses; Douglas A Fraker; David C Metz
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

10.  Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.

Authors:  Gabriele Carlinfante; Paola Baccarini; Debora Berretti; Tiziana Cassetti; Maurizio Cavina; Rita Conigliaro; Alessandro De Pellegrin; Luca Di Tommaso; Carlo Fabbri; Adele Fornelli; Andrea Frasoldati; Giorgio Gardini; Luisa Losi; Livia Maccio; Raffaele Manta; Nico Pagano; Romano Sassatelli; Silvia Serra; Lorenzo Camellini
Journal:  Virchows Arch       Date:  2014-05-08       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.